A Study To Compare Sirolimus Versus Tacrolimus In De Novo Simultaneous Pancreas- Kidney Allograft Recipients Receiving An Induction Therapy With Antithymocyte Globulin Plus Mycophenolate Mofetil Plus Corticosteroids
Information source: Nantes University Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pancreas Transplantation; Kidney Transplantation
Intervention: Sirolimus (Drug); Tacrolimus (Drug)
Phase: Phase 4
Status: Active, not recruiting
Sponsored by: Nantes University Hospital
Official(s) and/or principal investigator(s):
Diego CANTAROVICH, Doctor, Principal Investigator, Affiliation: CHU Nantes
Experience with tacrolimus in pancreas transplantation has become a standard for
immunosuppression in almost all pancreas centers over the world. Several centers have shown
very good results in simultaneous pancreas-kidney (SPK) transplant recipients receiving
antithymocyte globulin induction and maintenance immunosuppression consisting of calcineurin
inhibitor and mycophenolate mofetil with or without corticosteroids.
The use of sirolimus in SPK transplant patients has for the moment only been studied, with
good results, in association with tacrolimus or cyclospsorine (CsA). In renal
transplantation, there is also evidence that sirolimus (Rapamune) is a potent
immunosuppressant that significantly reduces the incidence of acute rejection when given
with CsA, effective as base therapy in the post-induction period. Because of Rapamune's
effectiveness and different safety profile, it might be advantageous in terms of reduced
nephrotoxicity to avoid completely calcineurin inhibitors without increased incidence of
To explore this further, the following study is designed to assess the use of SRL versus
TAC, both treatment groups including rATG plus MMF and a 3-month course of steroids in de
novo simultaneous pancreas-kidney transplant recipients.
Official title: An Open-Label, Comparative, Randomized, Prospective Study To Compare Sirolimus Versus Tacrolimus In De Novo Simultaneous Pancreas- Kidney Allograft Recipients Receiving An Induction Therapy With Antithymocyte Globulin Plus Mycophenolate Mofetil Plus Corticosteroids
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Kidney graft and pancreas graft survivals at month 12.
Incidence of histologically proven acute rejection episode at 3, 6, 12 months then annually up to 60 months.
Incidence of presumed clinical acute rejection at 3, 6, 12 months then annually up to 60 months.
Incidence of patient survival at 12 months then annually up to 60 months.
Incidence of renal graft survival annually up to 60 months.
Incidence of pancreas graft survival annually up to 60 months.
Time to the first acute rejection episode (time to the beginning of treatment of acute rejection episode).
Severity of rejection episodes including a histological grade of the first acute rejection episode.
Incidence of documented infection (culture, biopsy or serologically confirmed) or presumptive infection, including opportunistic infections at 3, 6, 12 months then annually up to 60 months.
Incidence of histologically-confirmed lymphoproliferative disease or malignancy at 12 months then annually up to 60 months.
Renal function assessed by creatinine clearance (Cockroft and Gault's formula) at 3, 6 and 12 months then annually up to 60 months.
Renal function assessed by serum creatinine at 3, 6 and 12 months then annually up to 60 months.
Incidence of renal Delayed Graft Function (DGF) defined as the need for more than one dialysis during the first week following transplantation.
Duration of renal Delayed Graft Function.
Incidence of renal Slow Graft Function (SGF) defined as serum creatinine ≥ 250 µmol/l at day 5 after transplantation (in the absence of dialysis).
Histology of renal graft will be assessed at month 12 if biopsy is not contra-indicated.
Pancreas graft function evaluated by hemoglobin A1C (HbA1C) at 3, 6 and 12 months then annually up to 60 months.
Pancreas graft function evaluated by basal glycemia at 3, 6 and 12 months then annually up to 60 months.
Pancreas graft function evaluated by stimulated glycemia levels at 6 and 12 months then annually up to 60 months.
Pancreas graft function evaluated by basal insulin secretion at 3, 6 and 12 months then annually up to 60 months.
Pancreas graft function evaluated by stimulated insulin secretion at 6 and 12 months then annually up to 60 months.
Incidence of hypertension (defined as systolic ≥ 140 mmgHG and/or diastolic ≥ 90 mmgHG and the use of antihypertensive medications including diuretics) at 3, 6 and 12 months then annually up to 60 months.
Number of antihypertensive drugs at 3, 6 and 12 months then annually up to 60 months.
Lipid levels (cholesterol, triglycerides, LDL-cholesterol, HDL-cholesterol) at 3, 6 and 12 months then annually up to 60 months.
Number of lipid lowering agents at 3, 6 and 12 months then annually up to 60 months.
The main objective is to compare renal and pancreas graft survivals at 12 months after
simultaneous pancreas-kidney transplantation in patients receiving either a regimen
combining sirolimus (SRL) plus mycophenolate mofetil (MMF) following an antibody induction
(rATG) or a regimen combining tacrolimus (TAC) plus mycophenolate mofetil following an
antibody induction (rATG). In both regimens corticosteroids (CS) will be withdrawn three
months after transplantation.
In addition, the two treatment groups will be compared for acute rejection, renal and
pancreas functions and patient survival after transplantation at 12 months and for a total
period of 5 years of follow-up.
Minimum age: 18 Years.
Maximum age: 60 Years.
- Recipient age ≥ 18 and ≤ 60 years.
- Patients receiving a first cadaveric simultaneous pancreas-kidney transplant for
insulin-dependent diabetes associated with end-stage renal disease.
- Women who are of childbearing potential must have a negative serum pregnancy test and
agree to use a medically acceptable method of contraception throughout the treatment
period and for 3 months following discontinuation.
- Signed and dated informed consent.
- Donor age ≤ 15 years and ≥ 60 years.
- Evidence of active systemic or localized major infection.
- Evidence of infiltrate, cavitation, or consolidation on chest x-ray.
- Use of any investigational drug or treatment (in particular immuno-suppressive drugs)
up to 4 weeks prior to enrollment to the study and during the 12-month treatment
- History of malignancy (with the exception of adequately treated localized squamous
cell or basal cell carcinoma, without recurrence within 5 years of enrolment into the
- Graft from a living donor.
- Double renal graft.
- Known hypersensitivity to sirolimus and its derivatives or to tacrolimus.
- Known hypersensitivity to rabbit's proteins.
- Multiple organ transplants or recipients of previously transplanted organs other than
- Treatment with cisapride (PrépulsidÒ), pimozide (OrapÒ), ketoconazole (NizoralÒ),
fluconazole (TriflucanÒ) or millepertuis (ProcalmilÒ, Arkogélules MillepertuisÒ),
that is not discontinued within 24 hours prior to transplant.
- Total white blood cell count ≤ 2 x 109/L or platelet count ≤ 70. 000/mm3 at baseline.
- Patients with evidence of active histological or biological hepatic disease during
the six months period before the transplantation.
- HIV positive recipients.
- Non-heart beating donor.
Locations and Contacts
CHU de Nantes, Nantes, France
Starting date: April 2004
Last updated: May 11, 2015